A Phase I Study of Intra-Arterial Yttrium-90 Radioembolization for Unresectable Pancreatic Cancer

This clinical study aims to evaluate the safety and tolerability of intra-arterial Yttrium-90 (90Y) glass microspheres in patients with unresectable pancreatic adenocarcinoma. The study will assess radiation dose distribution, adverse effects, and preliminary efficacy following selective arterial radioembolization.

Trial Details

NCT ID

NCT07898683

Phase

PHASE1

Sponsor

National Medical Research Radiological Centre of the Ministry of Health of Russia

Status

RECRUITING

Cancer Type

Pancreatic Cancer

Interventions

Transarterial Radioembolization

Locations (sample)

Obninsk, Russia|55.10993,36.61238

Key Eligibility Criteria

Histologically confirmed pancreatic adenocarcinoma (T4N0/1M0/1)
ECOG performance status 0-1, for at least 2 weeks
Life expectancy ≥12 weeks
Signed informed consent for participation

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Pancreatic Cancer Trials on Trialify →